Publications by authors named "EnYu Dai"

Article Synopsis
  • Scientists are using a new method called spatial transcriptomics (ST) to learn how cells interact in tumors, but current tools don't take important details into account.
  • They created a better tool called METI that helps to understand where cancer cells are and how they work together by looking at cell shapes and gene information.
  • METI has been tested on different types of cancer tissues and showed it works better than older tools in analyzing these complex cell environments.
View Article and Find Full Text PDF

Respiratory tract infections are the most common triggers for heart failure in elderly people. The healthy respiratory commensal microbiota can prevent invasion by infectious pathogens and decrease the risk of respiratory tract infections. However, upper respiratory tract (URT) microbiome in the elderly is not well understood.

View Article and Find Full Text PDF
Article Synopsis
  • Advanced gastric adenocarcinoma (GAC) is challenging to study due to difficulties in obtaining matched patient specimens, limiting insights into its metastatic biology and immune responses.
  • The research involved single-cell analysis of 68 treatment-naïve primary metastatic tumors, revealing unique characteristics of liver and peritoneal metastases and how cancer cells evolve with their environment.
  • Findings indicated that GAC cells evade ferroptosis, a form of cell death, which can be targeted to enhance the effectiveness of therapies like chimeric antigen receptor T-cell therapy.
View Article and Find Full Text PDF

Gastric cancer (GC) presents a formidable global health challenge, and conventional therapies face efficacy limitations. Ubiquitin-specific protease 7 (USP7) plays pivotal roles in GC development, immune response, and chemo-resistance, making it a promising target. Various USP7 inhibitors have shown selectivity and efficacy in preclinical studies.

View Article and Find Full Text PDF

Understanding the cellular processes that underlie early lung adenocarcinoma (LUAD) development is needed to devise intervention strategies. Here we studied 246,102 single epithelial cells from 16 early-stage LUADs and 47 matched normal lung samples. Epithelial cells comprised diverse normal and cancer cell states, and diversity among cancer cells was strongly linked to LUAD-specific oncogenic drivers.

View Article and Find Full Text PDF

Understanding tumor microenvironment (TME) reprogramming in gastric adenocarcinoma (GAC) progression may uncover novel therapeutic targets. Here, we performed single-cell profiling of precancerous lesions, localized and metastatic GACs, identifying alterations in TME cell states and compositions as GAC progresses. Abundant IgA plasma cells exist in the premalignant microenvironment, whereas immunosuppressive myeloid and stromal subsets dominate late-stage GACs.

View Article and Find Full Text PDF

Tumor-infiltrating T cells offer a promising avenue for cancer treatment, yet their states remain to be fully characterized. Here we present a single-cell atlas of T cells from 308,048 transcriptomes across 16 cancer types, uncovering previously undescribed T cell states and heterogeneous subpopulations of follicular helper, regulatory and proliferative T cells. We identified a unique stress response state, T, characterized by heat shock gene expression.

View Article and Find Full Text PDF

Background: Chimeric antigen receptor (CAR) T-cell therapy using brexucabtagene autoleucel (BA) induces remission in many patients with mantle cell lymphoma (MCL), and BA is the only CAR T-cell therapy approved by the FDA for MCL. However, development of relapses to BA is recognized with poor patient outcomes. Multiple CAR T-cell therapies have been approved for other lymphomas and the resistance mechanisms have been investigated.

View Article and Find Full Text PDF

Unlabelled: Tumor-infiltrating B and plasma cells (TIB) are prevalent in lung adenocarcinoma (LUAD); however, they are poorly characterized. We performed paired single-cell RNA and B-cell receptor (BCR) sequencing of 16 early-stage LUADs and 47 matching multiregion normal tissues. By integrative analysis of ∼50,000 TIBs, we define 12 TIB subsets in the LUAD and adjacent normal ecosystems and demonstrate extensive remodeling of TIBs in LUADs.

View Article and Find Full Text PDF
Article Synopsis
  • Follicular lymphoma (FL) is a type of B-cell cancer influenced by various immune cells, and researchers used single-cell RNA sequencing to explore its diverse cell populations and identify specific T-cell subsets.
  • They found four distinct FL subtypes, each with different T-cell characteristics linked to the expression of MHC molecules on FL cells, which impact how the immune system recognizes the tumor.
  • This study helps inform potential immunotherapy strategies by highlighting the importance of MHC expression in FL and identifying targetable immune checkpoints on T cells that vary between tumors with normal and low MHC expression.
View Article and Find Full Text PDF

Immune checkpoint therapy (ICT) provides substantial clinical benefits to cancer patients, but a large proportion of cancers do not respond to ICT. To date, the genomic underpinnings of primary resistance to ICT remain elusive. Here, we performed immunogenomic analysis of data from TCGA and clinical trials of anti-PD-1/PD-L1 therapy, with a particular focus on homozygous deletion of 9p21.

View Article and Find Full Text PDF

The mechanisms driving therapeutic resistance and poor outcomes of mantle cell lymphoma (MCL) are incompletely understood. We characterize the cellular and molecular heterogeneity within and across patients and delineate the dynamic evolution of tumor and immune cell compartments at single cell resolution in longitudinal specimens from ibrutinib-sensitive patients and non-responders. Temporal activation of multiple cancer hallmark pathways and acquisition of 17q are observed in a refractory MCL.

View Article and Find Full Text PDF
Article Synopsis
  • The study uses single-cell RNA sequencing to analyze 186,916 cells from early-stage lung adenocarcinoma (LUAD) and normal lung tissues, revealing how cell lineages and states evolve spatially from normal to cancerous regions.
  • Findings show significant intratumor heterogeneity in LUAD and variations in immune cell populations, with an increase in T regulatory cells near tumors and a decrease in cytotoxic CD8 T cells and other immune cell types in those areas.
  • Researchers present a spatial atlas of LUAD evolution that identifies potential therapeutic targets for early intervention, highlighting the need for further investigation of the peripheral lung's geospatial ecosystem.
View Article and Find Full Text PDF

Autologous chimeric antigen receptor (CAR) T cell therapies targeting CD19 have high efficacy in large B cell lymphomas (LBCLs), but long-term remissions are observed in less than half of patients, and treatment-associated adverse events, such as immune effector cell-associated neurotoxicity syndrome (ICANS), are a clinical challenge. We performed single-cell RNA sequencing with capture-based cell identification on autologous axicabtagene ciloleucel (axi-cel) anti-CD19 CAR T cell infusion products to identify transcriptomic features associated with efficacy and toxicity in 24 patients with LBCL. Patients who achieved a complete response by positron emission tomography/computed tomography at their 3-month follow-up had three-fold higher frequencies of CD8 T cells expressing memory signatures than patients with partial response or progressive disease.

View Article and Find Full Text PDF

The emergence and spread of drug-resistant Mycobacterium tuberculosis is of global concern. To improve the understanding of drug resistance in Mycobacteria, numerous studies have been performed to discover diagnostic markers and genetic determinants associated with resistance to anti-tuberculosis drug. However, the related information is scattered in a massive body of literature, which is inconvenient for researchers to investigate the molecular mechanism of drug resistance.

View Article and Find Full Text PDF

Drug repositioning has become a prevailing tactic as this strategy is efficient, economical and low risk for drug discovery. Meanwhile, recent studies have confirmed that small-molecule drugs can modulate the expression of disease-related miRNAs, which indicates that miRNAs are promising therapeutic targets for complex diseases. In this study, we put forward and verified the hypothesis that drugs with similar miRNA profiles may share similar therapeutic properties.

View Article and Find Full Text PDF

Selecting the available treatment for each cancer patient from genomic context is a core goal of precision medicine, but innovative approaches with mechanism interpretation and improved performance are still highly needed. Through utilizing in vitro chemotherapy response data coupled with gene and miRNA expression profiles, we applied a network-based approach that identified markers not as individual molecules but as functional groups extracted from the integrated transcription factor and miRNA regulatory network. Based on the identified chemoresponse communities, the predictors of drug resistance achieved high accuracy in cross-validation and were more robust and reproducible than conventional single-molecule markers.

View Article and Find Full Text PDF

Pathway enrichment analysis has been widely used to identify cancer risk pathways, and contributes to elucidating the mechanism of tumorigenesis. However, most of the existing approaches use the outdated pathway information and neglect the complex gene interactions in pathway. Here, we first reviewed the existing widely used pathway enrichment analysis approaches briefly, and then, we proposed a novel topology-based pathway enrichment analysis (TPEA) method, which integrated topological properties and global upstream/downstream positions of genes in pathways.

View Article and Find Full Text PDF

Summary: As a promising field of individualized therapy, non-coding RNA pharmacogenomics promotes the understanding of different individual responses to certain drugs and acts as a reasonable reference for clinical treatment. However, relevant information is scattered across the published literature, which is inconvenient for researchers to explore non-coding RNAs that are involved in drug resistance. To address this, we systemically identified validated and predicted drug resistance-associated microRNAs and long non-coding RNAs through manual curation and computational analysis.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers studied the role of plasma microRNAs (miRNAs) in diagnosing cavitary pulmonary tuberculosis (CP-TB) compared to non-cavitary patients and healthy controls using samples from 89 CP-TB patients, 89 NCP-TB patients, and 95 healthy individuals.
  • The study employed high-throughput sequencing and quantitative RT-PCR to identify 29 differentially expressed miRNAs, specifically validating miR-769-5p, miR-320a, and miR-22-3p as key indicators in distinguishing TB patients from healthy controls.
  • Results indicated that these miRNAs showed strong potential as blood-based biomarkers, with miR-320a also suggested as a marker for drug-resistant TB, highlighting
View Article and Find Full Text PDF

Adverse drug reactions (ADRs) are responsible for drug failure in clinical trials and affect life quality of patients. The identification of ADRs during the early phases of drug development is an important task. Therefore, predicting potential protein targets eliciting ADRs is essential for understanding the pathogenesis of ADRs.

View Article and Find Full Text PDF

MicroRNAs (miRNAs) are a class of small non-coding RNA molecules that regulate gene expression at post-transcriptional level. Increasing evidences show aberrant expression of miRNAs in varieties of diseases. Targeting the dysregulated miRNAs with small molecule drugs has become a novel therapy for many human diseases, especially cancer.

View Article and Find Full Text PDF

Background: Breast cancer is the most common incident form of cancer in women including different subtypes. Cancer stem cells (CSCs) have been confirmed to exist in breast cancer. But the research on the origin of breast cancer subtype stem cells (BCSSCs) is still inadequate.

View Article and Find Full Text PDF